(Q38511520)

3 September 2017

Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity (English)

1 reference

3 September 2017

Roya Zoraghi

1

1 reference

3 September 2017

Jackie D Corbin

series ordinal

2

1 reference

3 September 2017

Sharron H Francis

series ordinal

3

1 reference

3 September 2017

language of work or name

English

0 references

publication date

5 January 2006

1 reference

Journal of Biological Chemistry

3 September 2017

1 reference

3 September 2017

281

1 reference

3 September 2017

9

1 reference

3 September 2017

5553-5558

1 reference

PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization

3 September 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Crystal structure of phosphodiesterase 4D and inhibitor complex(1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

The Crystal Structure of AMP-Bound PDE4 Suggests a Mechanism for Phosphodiesterase Catalysis,

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Single step isolation of sildenafil from commercially available Viagra™ tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Functional group contributions to drug-receptor interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

PDE5 is converted to an activated state upon cGMP binding to the GAF A domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M510372200

21 January 2018

Identifiers

DOI

10.1074/JBC.M510372200

1 reference

3 September 2017

1 reference